Anatara is currently evaluating a range of evidence-based gastrointestinal consumer health products with a view to expand its current pipeline through in-licencing and distribution. In parallel, the Company continues to remain on-track to announce its human clinical trial protocol and the latest results from its preclinical animal studies for its Gastrointestinal ReProgramming dietary supplement for gut health, bringing the Company closer to partnering in 2020.
The Company remains focused on building a pipeline of evidence-based human gastrointestinal health products which will provide real outcomes for patients and drive value for its shareholders.
To view the video, please visit:
https://www.abnnewswire.net/press/en/99917/anr
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
Contact
Investor and Media inquiriesSteven Lydeamore
Chief Executive Officer
Anatara Lifesciences Ltd
T: +61-438-027-172
E: slydeamore@anatara.com
Sue MacLeman
Chair
Anatara Lifesciences Ltd
T: +61-437-211-200
E: smacleman@anatara.com
Related Companies
Related Industry Topics: